1
|
Reyes JM, Gutierrez MV, Madariaga H, Otero W, Guzman R, Izquierdo J, Abello M, Velez P, Castillo D, Ponce de Leon D, Lukic T, Amador L. Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries. Reumatol Clin (Engl Ed) 2023; 19:319-327. [PMID: 37286268 DOI: 10.1016/j.reumae.2023.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 02/03/2023] [Indexed: 06/09/2023]
Abstract
OBJECTIVE To describe efficacy, safety, and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) treated with tofacitinib or biological DMARDs (bDMARDs) in real-life conditions. METHODS A noninterventional study was performed between March 2017 and September 2019 at 13 sites in Colombia and Peru. Outcomes measured at baseline and at the 6-month follow-up were disease activity (RAPID3 [Routine Assessment of Patients Index Data] score), functional status (HAQ-DI [Health Assessment Questionnaire] score), and quality of life (EQ-5D-3L [EuroQol Questionnaire]). The Disease Activity Score-28 (DAS28-ESR) and frequency of adverse events (AEs) were also reported. Unadjusted and adjusted differences from baseline were estimated and expressed as the least squares mean difference (LSMD). RESULTS Data from 100 patients treated with tofacitinib and 70 patients with bDMARDs were collected. At baseline, the patients' mean age was 53.53 years (SD 13.77), the mean disease duration was 6.31 years (SD 7.01). The change from baseline at month 6 was not statistically significant different in the adjusted LSMD [SD] for tofacitinib vs. bDMARDs for RAPID3 score (-2.55[.30] vs. -2.52[.26]), HAQ-DI score (-.56[.07] vs. -.50[.08]), EQ-5D-3L score (.39[.04] vs. .37[.04]) and DAS28-ESR (-2.37[.22] vs. -2.77[.20]). Patients from both groups presented similar proportions of nonserious and serious AEs. No deaths were reported. CONCLUSION Changes from baseline were not statistically significantly different between tofacitinib and bDMARDs in terms of RAPID3 scores and secondary outcomes. Patients from both groups presented similar proportions of nonserious and serious AEs. CLINICAL TRIAL NUMBER NCT03073109.
Collapse
Affiliation(s)
| | | | - H Madariaga
- Centro Especializado de enfermedades neoplásicas (CEEN), Arequipa, Peru
| | - W Otero
- Centro Servimed, Bucaramanga, Colombia
| | - R Guzman
- Instituto de Enfermedades Autoinmunes Renato Guzmán (IDEARG), Bogota, Colombia
| | | | - M Abello
- Centro Integral de Reumatología Circaribe, Barranquilla, Colombia
| | - P Velez
- Centro de Investigación en Reumatología y Especialidades Médicas (CIREEM), Bogota, Colombia
| | | | | | | | | |
Collapse
|
2
|
Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang JE, Khoury J, Press MF, McBride H, Kim KK, Khazan N, Zhang Q, Zhang Y, Guzman R, Miller MC, Reuben J, Ueno NT. Abstract P5-06-01: A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System in support of FDA clearance. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p5-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a non-invasive surrogate source of tumor material to investigate tumor characteristics in real-time. However, the only FDA-cleared CTC assay is limited to the enumeration of surface marker-defined epithelial cells and not designed for further characterization of the CTCs identified. The Parsortix® PC1 system is a semi-automated microfluidic device capable of capturing and harvesting CTCs from peripheral blood based on cell size and deformability, making it cell-surface marker agnostic. Here, we demonstrate that the Parsortix® PC1 system enables the enrichment and capture of CTCs from the blood of patients with metastatic breast cancer (MBC) and their interrogation using evaluation techniques commonly available in clinical laboratories. Methods: As part of a multicenter clinical trial (NCT03427450), peripheral blood samples from 216 patients with MBC and 205 healthy volunteers (HVs) were prospectively collected at four different clinical sites located throughout the United States. Each subject provided two separate blood samples collected into K2EDTA Vacutainer® tubes to be processed using the Parsortix® PC1 system on the same day. The cells harvested from one of the blood samples collected from each subject by the Parsortix® PC1 system were deposited onto cytology slides using a cytocentrifugation method and stained with Wright-Giemsa reagents using an automated stainer. The stained slides were subjected to cytopathological evaluation by a board-certified pathologist to enumerate CTCs. As proof of principle, cells harvested from the second blood sample were evaluated using one of three additional techniques: molecular profiling by qRT-PCR, RNA sequencing, or cytogenetic analysis of HER2 amplification by FISH. Results: Cytologic examination identified one or more cells as a CTC in 48.5% (95% CI of 41.5 – 55.4%) of the 194 patients with MBC and 9.9% (95% CI of 6.4 – 14.9%) of the 192 HVs. The results from the qRT-PCR evaluation (102 HVs and 74 MBC patients) showed differential expression of cancer-related genes (KRT19, EPCAM, and TWIST1) in the patients with MBC compared to the HVs. Results from the RNA sequencing (53 HVs and 16 MBC patients) showed differential expression of several genes involved in the Kegg Cancer Pathway in the patients with MBC compared to the HVs. The results from the HER2 FISH evaluation (38 HVs and 101 MBC patients) showed that while the majority of the CTC identified had normal HER2/CEP17 ratios, detection of HER2 amplification was possible. Conclusions: The Parsortix PC1 system is capable of capturing and harvesting CTCs from the peripheral blood of patients with MBC. Harvested cells can be evaluated using standard orthogonal methodologies such as gene expression and FISH to identify and characterize CTCs. Based in part on the above results, the FDA granted a De Novo classification request (DEN200062) for the Parsortix PC1 device in May of 2022.
Citation Format: Evan Cohen, Gitanjali Jayachandran, Richard Moore, Massimo Cristofanilli, Julie E. Lang, Joseph Khoury, Michael F. Press, Heather McBride, Kyu Kwang Kim, Negar Khazan, Qiang Zhang, Youbin Zhang, Roberta Guzman, Michael C. Miller, James Reuben, Naoto T. Ueno. A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System in support of FDA clearance [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-06-01.
Collapse
Affiliation(s)
- Evan Cohen
- 1University of Texas MD Anderson Cancer Center
| | | | - Richard Moore
- 3Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
| | | | | | | | - Michael F. Press
- 7Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | | | | | | | - Qiang Zhang
- 11Northwestern University Feinberg School of Medicine
| | - Youbin Zhang
- 12Northwestern Medicine Northwestern University, Chicago, Illinois
| | | | | | | | - Naoto T. Ueno
- 16The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
3
|
Cohen EN, Jayachandran G, Moore RG, Cristofanilli M, Lang JE, Khoury JD, Press MF, Kim KK, Khazan N, Zhang Q, Zhang Y, Kaur P, Guzman R, Miller MC, Reuben JM, Ueno NT. A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix ® PC1 System. Cancers (Basel) 2022; 14:5238. [PMID: 36358657 PMCID: PMC9656921 DOI: 10.3390/cancers14215238] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 10/18/2022] [Accepted: 10/20/2022] [Indexed: 08/22/2023] Open
Abstract
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material that can be obtained via a venipuncture (also known as a liquid biopsy) and used to better understand tumor characteristics. However, the only FDA-cleared CTC assay has been limited to the enumeration of surface marker-defined cells and not further characterization of the CTCs. In this study, we tested the ability of a semi-automated device capable of capturing and harvesting CTCs from peripheral blood based on cell size and deformability, agnostic of cell-surface markers (the Parsortix® PC1 System), to yield CTCs for evaluation by downstream techniques commonly available in clinical laboratories. The data generated from this study were used to support a De Novo request (DEN200062) for the classification of this device, which the FDA recently granted. As part of a multicenter clinical trial, peripheral blood samples from 216 patients with metastatic breast cancer (MBC) and 205 healthy volunteers were subjected to CTC enrichment. A board-certified pathologist enumerated the CTCs from each participant by cytologic evaluation of Wright-Giemsa-stained slides. As proof of principle, cells harvested from a concurrent parallel sample provided by each participant were evaluated using one of three additional evaluation techniques: molecular profiling by qRT-PCR, RNA sequencing, or cytogenetic analysis of HER2 amplification by FISH. The study demonstrated that the Parsortix® PC1 System can effectively capture and harvest CTCs from the peripheral blood of MBC patients and that the harvested cells can be evaluated using orthogonal methodologies such as gene expression and/or Fluorescence In Situ Hybridization (FISH).
Collapse
Affiliation(s)
- Evan N. Cohen
- Department of Hematopathology Research, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Gitanjali Jayachandran
- Department of Hematopathology Research, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Richard G. Moore
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14620, USA
| | - Massimo Cristofanilli
- Department of Medicine-Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Julie E. Lang
- USC Breast Cancer Program, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | - Joseph D. Khoury
- Department of Pathology, Breast Cancer Analysis Laboratory, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | - Michael F. Press
- Department of Pathology, Breast Cancer Analysis Laboratory, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | - Kyu Kwang Kim
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14620, USA
| | - Negar Khazan
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14620, USA
| | - Qiang Zhang
- Department of Medicine-Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Youbin Zhang
- Department of Medicine-Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Pushpinder Kaur
- USC Breast Cancer Program, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | - Roberta Guzman
- Department of Pathology, Breast Cancer Analysis Laboratory, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
| | - Michael C. Miller
- ANGLE Clinical Studies, ANGLE Europe Limited, Guildford, Surrey GU2 7AF, UK
| | - James M. Reuben
- Department of Hematopathology Research, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Naoto T. Ueno
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| |
Collapse
|
4
|
Gutierrez-Ardila MV, Reyes J, Madariaga H, Otero W, Guzman R, Izquierdo J, Abello M, Velez P, Castillo D, Ponce de Leon D, Lukic T, Amador L. Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs. Expert Rev Pharmacoecon Outcomes Res 2022; 22:787-794. [PMID: 35249439 DOI: 10.1080/14737167.2022.2047935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To evaluate work productivity of adult Latin American patients with rheumatoid arthritis (RA) treated with tofacitinib and biological disease-modifying anti-rheumatic drugs (bDMARDs) measured by the Work Productivity and Activity Impairment (WPAI) in RA questionnaire at 0- and 6-month follow-up. METHODS This non-interventional study was performed in Colombia and Peru. Evaluated the effects of tofacitinib and bDMARDs in patients with RA after failure of conventional DMARDs. The WPAI-RA questionnaire was administered at baseline and at the 6-month (±1 month) follow-up. The results are expressed as least squares means (LSMs), and standard errors (SEs). RESULTS One hundred patients treated with tofacitinib and 70 patients treated with bDMARDs were recruited. Twenty-eight percent of patients from the tofacitinib group and 40.0% from the bDMARDs group were working for pay at baseline. At month 6, the changes in absenteeism, presenteeism, and work impairment due to health were -18.3% (SE 7.7), -34.8% (SE 5.9), and -11.0% (SE 16.5), respectively, in the tofacitinib group and -19.4% (SE 8.0), -34.8% (SE 6.2), and -15.9% (SE 15.0), for the bDMARD group. CONCLUSION For patients who reported working, there were improvements in presenteeism, absenteeism, and work impairment due to health in both groups. TRIAL REGISTRATION NCT03073109.
Collapse
Affiliation(s)
| | | | - H Madariaga
- Rheumatology, Centro Médico CEEN, Arequipa, Peru
| | - W Otero
- Rheumatology, Centro Servimed, Bucaramanga, Colombia
| | - R Guzman
- Rheumatology, Centro IDEARG, Bogotá, Colombia
| | - J Izquierdo
- Rheumatology, Clínica del Occidente, Cali, Colombia
| | - M Abello
- Rheumatology, Centro Integral de Reumatología Circaribe, Barranquilla, Colombia
| | - P Velez
- Rheumatology, Centro Médico CIREEM, Bogotá, Colombia
| | - D Castillo
- Rheumatology, Clínica del Occidente, Cali, Colombia
| | | | - T Lukic
- Medical department, Pfizer Inc, New York, USA
| | | |
Collapse
|
5
|
Thomale UW, Auer C, Spennato P, Schaumann A, Behrens P, Gorelyshev S, Bogoslovskaia E, Shulaev A, Kabanian A, Seliverstov A, Alexeev A, Ozgural O, Kahilogullari G, Schuhmann M, Jimenez-Guerra R, Wittayanakorn N, Sukharev A, Marquez-Rivas J, Linsler S, Damaty AE, Vacek P, Lovha M, Guzman R, Stricker S, Beez T, Wiegand C, Azab M, Buis D, Sáez M, Fleck S, Dziugan C, Ferreira A, Radovnicky T, Bührer C, Lam S, Sgouros S, Roth J, Constantini S, Cavalheiro S, Cinalli G, Kulkarni AV, Bock HC. TROPHY registry - status report. Childs Nerv Syst 2021; 37:3549-3554. [PMID: 34184098 PMCID: PMC8578079 DOI: 10.1007/s00381-021-05258-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Accepted: 06/08/2021] [Indexed: 11/25/2022]
Abstract
INTRODUCTION The TROPHY registry has been established to conduct an international multicenter prospective data collection on the surgical management of neonatal intraventricular hemorrhage (IVH)-related hydrocephalus to possibly contribute to future guidelines. The registry allows comparing the techniques established to treat hydrocephalus, such as external ventricular drainage (EVD), ventricular access device (VAD), ventricular subgaleal shunt (VSGS), and neuroendoscopic lavage (NEL). This first status report of the registry presents the results of the standard of care survey of participating centers assessed upon online registration. METHODS On the standard of treatment forms, each center indicated the institutional protocol of interventions performed for neonatal post-hemorrhagic hydrocephalus (nPHH) for a time period of 2 years (Y1 and Y2) before starting the active participation in the registry. In addition, the amount of patients enrolled so far and allocated to a treatment approach are reported. RESULTS According to the standard of treatment forms completed by 56 registered centers, fewer EVDs (Y1 55% Y2 46%) were used while more centers have implemented NEL (Y1 39%; Y2 52%) to treat nPHH. VAD (Y1 66%; Y2 66%) and VSGS (Y1 42%; Y2 41%) were used at a consistent rate during the 2 years. The majority of the centers used at least two different techniques to treat nPHH (43%), while 27% used only one technique, 21% used three, and 7% used even four different techniques. Patient data of 110 infants treated surgically between 9/2018 and 2/2021 (13% EVD, 15% VAD, 30% VSGS, and 43% NEL) were contributed by 29 centers. CONCLUSIONS Our results emphasize the varying strategies used for the treatment of nPHH. The international TROPHY registry has entered into a phase of growing patient recruitment. Further evaluation will be performed and published according to the registry protocol.
Collapse
Affiliation(s)
- U. W. Thomale
- Pediatric Neurosurgery, Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin Augustenburger Platz 1, 13353 Berlin, Germany
| | - C. Auer
- Division of Pediatric Neurosurgery, Kepler Universitätsklinikum, Linz, Austria
| | - P. Spennato
- Pediatric Neurosurgery, AORN Santobono Pausilipon, Naples, Italy
| | - A. Schaumann
- Pediatric Neurosurgery, Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin Augustenburger Platz 1, 13353 Berlin, Germany
| | - P. Behrens
- Pediatric Neurosurgery, Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin Augustenburger Platz 1, 13353 Berlin, Germany
| | - S. Gorelyshev
- Pediatric Neurosurgery, Moscow Bashlyaeva Pediatric Hospital, Moscow, Russia
| | - E. Bogoslovskaia
- Pediatric Neurosurgery, Surgut Clinical Perinatal Center, Surgut, Russia
| | - A. Shulaev
- Pediatric Neurosurgery, Children’s Republic Clinical Hospital, Kazan, Russia
| | - A. Kabanian
- Pediatric Neurosurgery, Children’s Regional Hospital, Krasnodar, Russia
| | - A. Seliverstov
- Pediatric Neurosurgery, Kemerovo Regional Pediatric Hospital, Kemerovo, Russia
| | - A. Alexeev
- Pediatric Neurosurgery, Chelyabinsk Regional Children’s Clinical Hospital, Chelyabinsk, Russia
| | - O. Ozgural
- Neurosurgery, Ankara University, Ankara, Turkey
| | | | - M. Schuhmann
- Pediatric Neurosurgery, University Hospital of Tübingen, Tubingen, Germany
| | - R. Jimenez-Guerra
- Neonatal Neurosurgery, National Institute of Perinatology, Mexico City, Mexico
| | - N. Wittayanakorn
- Surgery, Queen Sirikit National Institute of Child Health, Bangkok, Thailand
| | - A. Sukharev
- Pediatric Neurosurgery, Regional Children Hospital, Yekaterinburg, Russia
| | | | - S. Linsler
- Neurosurgery, Saarland University Hospital, Homburg, Saarland Germany
| | - A. El Damaty
- Pediatric Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany
| | - P. Vacek
- Neurosurgery, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
| | - M. Lovha
- Neurosurgery, Volyn Regional Pediatric Hospital, Lutsk, Ukraine
| | - R. Guzman
- Neurosurgery, Universitätskinderspital Beider Basel, Basel, Switzerland
| | - S. Stricker
- Neurosurgery, Universitätskinderspital Beider Basel, Basel, Switzerland
| | - T. Beez
- Neurosurgery, Heinrich-Heine-University, Duesseldorf, Germany
| | - C. Wiegand
- Neurosurgery, Marienhospital, Osnabrück, Germany
| | - M. Azab
- Neurosurgery, Damietta Specialized Hospital, Damietta, Egypt
| | - D. Buis
- Neurosurgery, Amsterdam University Medical Centres, Amsterdam, Netherlands
| | - M. Sáez
- Neurosurgery, Hospital La Paz, Madrid, Spain
| | - S. Fleck
- Neurosurgery, University Medicine Greifswald, Greifswald, Germany
| | - C. Dziugan
- Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, USA
| | - A. Ferreira
- Neurosurgery, Centro Hospitalar Universitário São João, Porto, Portugal
| | - T. Radovnicky
- Neurosurgery, Masaryk Hospital, Usti Nad Labem, Czech Republic
| | - C. Bührer
- Pediatric Neurosurgery, Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin Augustenburger Platz 1, 13353 Berlin, Germany
| | - S. Lam
- Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, USA
| | - S. Sgouros
- Pediatric Neurosurgery, Iaso Childrens Hospital, Athens, Greece
| | - J. Roth
- Pediatric Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel
| | - S. Constantini
- Pediatric Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel
| | - S. Cavalheiro
- Pediatric Neurosurgery, Federal University of Sao Paulo, Sao Paulo, Brazil
| | - G. Cinalli
- Pediatric Neurosurgery, AORN Santobono Pausilipon, Naples, Italy
| | - A. V. Kulkarni
- Pediatric Neurosurgery, Sick Children Hospital, University of Toronto, Toronto, Canada
| | - H. C. Bock
- Pediatric Neurosurgery, University Medical Center Göttingen, Gottingen, Germany
| |
Collapse
|
6
|
Citera G, Jain R, Irazoque-Palazuelos F, Guzman R, Madariaga H, Gruben DC, Wang L, Stockert L, Hsu MA, Santana K, Ebrahim A, Ponce de Leon D. THU0196 TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INDICATIVE OF DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 CLINICAL TRIALS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023]
Abstract
Background:Depression/anxiety are common in RA pts. SF-36 MCS ≤38 can identify probable major depressive disorder and/or probable generalised anxiety disorder (pMDD/pGAD) in RA pts. Tofacitinib is an oral JAK inhibitor for the treatment of RA.Objectives:To assess pMDD/pGAD prevalence in the tofacitinib RA program and efficacy by baseline (BL) pMDD/pGAD status.Methods:Data from pts receiving tofacitinib, ADA, or PBO were pooled from 5 Phase (P)3 and 1 P3b/4 trials. Demographics/BL characteristics were reported by BL pMDD/pGAD (SF-36 MCS ≤38, presence; >38, absence). Month (M)3/6/9/12 SF-36 MCS change from BL (Δ) was estimated, and % with pMDD/pGAD reported. M3/6/12 efficacy outcomes compared tofacitinib-treated pts by BL pMDD/pGAD.Results:BL pMDD/pGAD was seen in 44.5% (tofacitinib 5 mg BID), 39.8% (tofacitinib 10 mg BID), 45.4% (ADA 40 mg Q2W) and 39.1% (PBO) of pts. pMDD/pGAD pts had higher BL CRP and worse disability, fatigue, pain and sleep vs pts without. SF-36 MCS increases were greater for tofacitinib vs PBO/ADA (Fig 1a). The % of pts with BL pMDD/pGAD who continued to have pMDD/pGAD reduced over time, and was generally lower for tofacitinib vs PBO/ADA (Fig 1b). Regardless of BL pMDD/pGAD, efficacy was generally similar for tofacitinib 5 mg BID (Table) and 10 mg BID.Conclusion:~40% of RA pts had BL pMDD/pGAD. SF-36 MCS improvements were greater for tofacitinib vs PBO/ADA. With tofacitinib, % of pts with SF-36 MCS ≤38 reduced by ~60% at M12. Tofacitinib efficacy was similar in pts with/without BL pMDD/pGAD. Limitations include using SF-36 MCS to identify probable rather than confirmed MDD or GAD. Future research using gold standard psychiatric interviews to validate use of SF-36 MCS ≤38 is needed.Table.M3/6/12 efficacy with tofacitinib 5 mg BID, by BL pMDD/pGADaSF-36 MCS ≤38SF-36 MCS >38OR (95% CI)P valueACR20 (%)b,cM355.157.90.89 (0.74, 1.08)0.2330M661.762.80.96 (0.79, 1.16)0.6511M1258.458.60.99 (0.80, 1.22)0.9279ACR50 (%)b,cM325.929.20.85 (0.70, 1.03)0.1022M636.038.00.92 (0.76, 1.11)0.3724M1233.834.30.98 (0.80, 1.20)0.8366ACR70 (%)b,cM310.111.00.91 (0.69, 1.18)0.4704M616.516.51.00 (0.79, 1.26)0.9901M1218.317.51.06 (0.83, 1.34)0.6560DAS28-4(ESR)<2.6 (%)b,cM35.47.40.72 (0.49, 1.05)0.0872M65.98.50.68 (0.49, 0.94)0.0199*M128.011.90.64 (0.47, 0.89)0.0073**ΔHAQ-DI, LS meanc,dSF-36 MCS ≤38SF-36 MCS >38Difference (95% CI)P valueM3-0.41-0.430.01 (-0.04, 0.06)0.6008M6-0.49-0.48-0.01 (-0.06, 0.04)0.6617M12-0.52-0.52-0.01 (-0.06, 0.05)0.8475*p<0.05; **p<0.01 Data pooled from 5 P3 and 1 P3b/4 tofacitinib trialsaBL pMDD/pGAD = SF-36 MCS ≤38;bLogistic regression fit;cFor PBO pts advancing to tofacitinib post-M3, only PBO data were included;dMixed-effects linear model fitΔ, change from baseline; ACR, American College of Rheumatology; BID, twice daily; BL, baseline; CI, confidence interval; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; LS, least squares; M, month; MCS, Mental Component Summary score; OR, odds ratio; P, Phase; pGAD, probable generalised anxiety disorder; PBO, placebo; pMDD, probable major depressive disorder; pt, patient; RA, rheumatoid arthritis; SF-36, Short Form-36 health surveyAcknowledgments:Study sponsored by Pfizer Inc. Medical writing support was provided by Sarah Piggott of CMC Connect and funded by Pfizer Inc.Disclosure of Interests:Gustavo Citera Grant/research support from: AbbVie, Amgen, Eli Lilly, Gema, Genzyme, Novartis and Pfizer Inc, Consultant of: AbbVie, Amgen, Eli Lilly, Gema, Genzyme, Novartis and Pfizer Inc, Rakesh Jain Grant/research support from: Allergan, Eli Lilly, Lundbeck, Otsuka, Pfizer Inc, Shire and Takeda, Consultant of: Acadia, Alfasigma, Allergan, Eisai, Eli Lilly, Evidera, Impel, Janssen, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer Inc, Shire, Sunovion, Supernus, Takeda and Teva, Speakers bureau: Alkermes, Allergan, Eli Lilly, Janssen, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer Inc, Shire, Sunovion, Takeda, Teva and Tris Pharmaceuticals, Fedra Irazoque-Palazuelos Consultant of: Bristol-Myers Squibb, Janssen, Pfizer Inc, Roche and UCB, Renato Guzman: None declared, Hugo Madariaga: None declared, David C Gruben Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Lisy Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Lori Stockert Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Ming-Ann Hsu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Karina Santana Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Abbas Ebrahim Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Dario Ponce de Leon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc
Collapse
|
7
|
Soler L, Jareño J, Banchewski J, Rasi S, Chamorro N, Guzman R, Yáñez R, Mocuta C, Ricart S, Farjas J, Roura-Grabulosa P, Obradors X, Puig T. Ultrafast transient liquid assisted growth of high current density superconducting films. Nat Commun 2020; 11:344. [PMID: 31953396 PMCID: PMC6969047 DOI: 10.1038/s41467-019-13791-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 11/29/2019] [Indexed: 11/10/2022] Open
Abstract
The achievement of high growth rates in YBa2Cu3O7 epitaxial high-temperature superconducting films has become strategic to enable high-throughput manufacturing of long length coated conductors for energy and large magnet applications. We report on a transient liquid assisted growth process capable of achieving ultrafast growth rates (100 nm s−1) and high critical current densities (5 MA cm−2 at 77 K). This is based on the kinetic preference of Ba-Cu-O to form transient liquids prior to crystalline thermodynamic equilibrium phases, and as such is a non-equilibrium approach. The transient liquid-assisted growth process is combined with chemical solution deposition, proposing a scalable method for superconducting tapes manufacturing. Additionally, using colloidal solutions, the growth process is extended towards fabrication of nanocomposite films for enhanced superconducting properties at high magnetic fields. Fast acquisition in situ synchrotron X-ray diffraction and high resolution scanning transmission electron microscopy (STEM) become crucial measurements in disentangling key aspects of the growth process. High throughput manufacturing of long length coated conductors requires fast epitaxial growth of high-temperature superconducting films. Here, Soler et al. report an ultrafast growth rates and high critical current densities of YBa2Cu3O7 films using a transient liquid-assisted growth method.
Collapse
Affiliation(s)
- L Soler
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain
| | - J Jareño
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain
| | - J Banchewski
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain
| | - S Rasi
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain.,GRMT, Department of Physics, Universitat de Girona, Campus Montilivi, Edif. PII, E17003, Girona, Catalonia, Spain
| | - N Chamorro
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain.,Departament de Química, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
| | - R Guzman
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain
| | - R Yáñez
- Departament de Química, Universitat Autònoma de Barcelona, 08193, Bellaterra, Catalonia, Spain
| | - C Mocuta
- Synchrotron SOLEIL, L'Orme des Merisiers Saint-Aubin BP 48, 91192, Gif-sur-Yvette, France
| | - S Ricart
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain
| | - J Farjas
- GRMT, Department of Physics, Universitat de Girona, Campus Montilivi, Edif. PII, E17003, Girona, Catalonia, Spain
| | - P Roura-Grabulosa
- GRMT, Department of Physics, Universitat de Girona, Campus Montilivi, Edif. PII, E17003, Girona, Catalonia, Spain
| | - X Obradors
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain
| | - T Puig
- Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193, Bellaterra, Catalonia, Spain.
| |
Collapse
|
8
|
Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncol 2019; 5:366-375. [PMID: 30520947 PMCID: PMC6439848 DOI: 10.1001/jamaoncol.2018.6012] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Importance The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an "equivocal" category (average HER2 copies per tumor cell ≥4-6 with HER2/CEP17 ratio <2.0) to be resolved as negative or positive by assessments with alternative control probes. Approximately 4% to 12% of all invasive breast cancers are characterized as HER2-equivocal based on FISH. Objective To evaluate the following hypotheses: (1) genetic loci used as alternative controls are heterozygously deleted in a substantial proportion of breast cancers; (2) use of these loci for assessment of HER2 by FISH leads to false-positive assessments; and (3) these HER2 false-positive breast cancer patients have outcomes that do not differ from clinical outcomes for patients with HER2-negative breast cancer. Design, Setting, and Participants We retrospectively assessed the use of chromosome 17 p-arm and q-arm alternative control genomic sites (TP53, D17S122, SMS, RARA, TOP2A), as recommended by the 2013/2014 ASCO-CAP guidelines for HER2 testing, in patients whose data were available through Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and whose tissues were available through the Breast Cancer International Research Group clinical trials. We used data from an international cohort database of invasive breast cancers (1980 participants) and international clinical trial of adjuvant chemotherapy in invasive, node-positive breast cancer patients. Main Outcomes and Measures The primary objectives were to (1) assess frequency of heterozygous deletions in chromosome 17 genomic sites used as FISH internal controls for evaluation of HER2 status among HER2-equivocal cancers; (2) characterize impact of using deleted sites for determination of HER2-to-internal-control-gene ratios; (3) assess HER2 protein expression in each subgroup; and (4) compare clinical outcomes for each subgroup. Results Of the 1980 patients in METABRIC,1915 patients were fully evaluated. In addition, 100 HER2-equivocal breast cancers by FISH and 100 comparator FISH-negative breast cancers from the BCIRG-005 trial were analyzed. Heterozygous deletions, particularly in specific p-arm sites, were common in both HER2-amplified and HER2-not-amplified breast cancers. Use of alternative control probes from these regions to assess HER2 by FISH in HER2-equivocal as well as HER2-not-amplified breast cancers resulted in high rates of false-positive ratios (HER2-to-alternative control ratio ≥2.0) owing to heterozygous deletions of control p-arm genomic sites used in ratio denominators. Misclassification of HER2 status was observed not only in breast cancers with ASCO-CAP equivocal status but also in breast cancers with an average of fewer than 4.0 HER2 copies per tumor cell when using alternative control probes. Conclusions and Relevance The indiscriminate use of alternative control probes to calculate HER2 FISH ratios in HER2-equivocal breast cancers may lead to false-positive interpretations of HER2 status resulting from unrecognized heterozygous deletions in 1 or more of these alternative control genomic sites and incorrect HER2 ratio determinations.
Collapse
Affiliation(s)
- Michael F Press
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles
| | - Jose A Seoane
- Departments of Medicine & Genetics, Stanford University, Stanford, California
| | - Christina Curtis
- Departments of Medicine & Genetics, Stanford University, Stanford, California
| | - Emmanuel Quinaux
- International Drug Development Institute, Louvain-la-Neuve, Belgium
| | - Roberta Guzman
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles
| | | | | | - John R Mackey
- Department of Oncology, University of Alberta, Edmonton, Canada
| | - Nicholas Robert
- Virginia Cancer Specialists/US Oncology Research Network, Fairfax, Virginia
| | | | - John Crown
- Irish Cooperative Oncology Research Group, St Vincent's University Hospital, Dublin, Ireland
| | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
| | - Vicente Valero
- The University of Texas, M.D. Anderson Cancer Center, Houston, Texas
| | - Valerie Bee
- Cancer International Research Group/Translational Research in Oncology, Paris, France
| | - Yanling Ma
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles
| | - Ivonne Villalobos
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles
| | - Dennis J Slamon
- Department of Medicine, Geffen School of Medicine at University of California Los Angeles, Los Angeles
| |
Collapse
|
9
|
Chen HW, Von Euw E, Millan P, Fresco R, Carrez S, Afenjar K, Fung H, Burton M, Santiago A, Guzman R, Villalobos I, Press M, Eiermann W, Slamon D. Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. Abstract PD3-11: HER2/ ERBB2 status in “ HER2 equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd3-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. The ASCO-CAP guidelines for HER2 testing by fluorescence in situ hybridization (FISH) have a category, referred to as “equivocal” (average HER2 copies per tumor cell >4-6 with HER2/CEP17 ratio <2·0), which is neither “HER2-positive” nor “HER2-negative”. Approximately 4% - 12% of invasive breast cancers are “HER2-equivocal” based on FISH. Cancers in this category may be resolved as “negative” or “positive” by FISH alternative control probes (2013/2014 guidelines) or HER2 immunohistochemistry (IHC) (2018 update). Our objectives were to evaluate the following hypotheses: 1.) Genetic loci used as alternative controls show heterozygous deletion in a substantial proportion of breast cancers; 2.) Use of these loci for assessment of HER2 by FISH leads to false-positives; 3.) HER2 FISH false-positive breast cancer patients have outcomes that do not differ from clinical outcomes for HER2-negative breast cancer patients; and 4.) HER2-equivocal breast cancers seldom show HER2 protein overexpression (IHC 3+).
Methods. We retrospectively assessed the use of chromosome 17 p-arm and q-arm alternative control genomic sites (TP53, D17S122, SMS, RARA, TOP2A), as recommended by the 2013/2014 ASCO-CAP guidelines, in patients whose data were available through the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)(N=1980) or whose tissues were available from the BCIRG-005 clinical trial (N=3298). We used either FDA-approved HER2 IHC (HercepTest) or laboratory-developed HER2 (10H8) IHC assays to assess HER2 protein expression.
Results. Using METABRIC we found heterozygous deletions, particularly in specific p-arm sites, were common in both HER2-amplified and HER2-not-amplified breast cancers. Use of alternative control probes from these regions to assess HER2 by FISH in “HER2 equivocal” as well as HER2-not-amplified breast cancers resulted in high rates of false-positive ratios (HER2-to-alternative control ratio >2·0) due to heterozygous deletions of control p-arm genomic sites used as ratio denominators. Misclassifications of HER2 status was observed not only in breast cancers with ASCO-CAP “equivocal” status but also in breast cancers with an average of <4·0 HER2 copies per tumor cell. These deletions were also identified by FISH. IHC demonstrated <1% of FISH “HER2-equivocal” breast cancers in BCIRG-005 had IHC3+ immunostaining, consistent with HER2-not-amplified status. Clinical outcomes of “HER2-equivocal” breast cancer patients with HER2-to-alternative control ratio >2·0 did not differ significantly from clinical outcomes of those with HER2-to-alternative control ratio<2·0.
Conclusion. Using chromosome 17 p-arm alternative controls, as recommended by 2013/2014 ASCO-CAP guidelines, instead of CEP17 for resolution of “HER2 equivocal” cases, is problematic due to frequent heterozygous deletions of these loci in breast cancers. The indiscriminate use of alternative control probes to calculate a HER2 FISH ratio in “HER2-equivocal” breast cancers leads to false-positive interpretations of HER2 status resulting from unrecognized heterozygous deletions in one or more of these alternative control genomic sites and incorrect HER2 ratio determinations.
Citation Format: Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. HER2/ERBB2 status in “HER2 equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD3-11.
Collapse
Affiliation(s)
- MF Press
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - JA Seoane
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - C Curtis
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - E Quinaux
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - R Guzman
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - G Sauter
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - W Eiermann
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - JR Mackey
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - N Robert
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - T Pienkowski
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - J Crown
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - M Martin
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - V Valero
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - V Bee
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - Y Ma
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - I Villalobos
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| | - DJ Slamon
- USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Stanford University, Stanford, CA; International Drug Development Institute, Louvain-la-Neuve, Belgium; University of Hamburg, Hamburg, Germany; Frauenklinik vom Roten Kreuz, Munich, Germany; University of Alberta, Edmonton, Canada; Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Postgraduate Medical Education Center, Warsaw, Poland; St Vincent's University Hospital, Dublin, Ireland; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; M.D. Anderson Cancer Center, Houston, TX; Cancer International Research Group/Translational Research in Oncology, Paris, France; Geffen School of Medicine at UCLA, Los Angeles, CA
| |
Collapse
|
11
|
Guirao A, Molins L, Guzman R, Cleries M, Vela E, Magen D, Sanchez D, Boada M, Espinas J, Borras J, Argimon J, Agusti A. P3.11-16 Comparative Analysis of Health-Care Resources and Economic Costs of Lung Cancer Patients Treated Medically or Surgically in Catalunya. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
12
|
Montesinos Encalada M, Boada M, Sanchez D, Libreros A, Guirao A, Guzman R, Gimferrer J, Molins L. P2.01-72 Bronchial Sleeve vs Pneumonectomy: Complications, Recurrences and Survival. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Guirao A, Molins L, Ramon I, Sunyer G, Vinolas N, Marrades R, Sanchez D, Fibla J, Hernandez J, Boada M, Guzman R, Libreros A, Agusti A. MA03.11 Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Carriel N, González D, Guzman R, Sanchez-Lorente D, Montes AG, Boada M, Gimferrer JM, Gómez-Caro A, Molins L. P-165HAEMOTHORAX SECONDARY TO CHEST WALL ARTERIAL LESION: OUR EXPERIENCE WITH TRANSCATHETER ARTERIAL EMBOLIZATION. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Hanf DC, Fasching PA, Villalobos IE, Gasparyan A, Wachter D, Santiago A, Guzman R, Weihbrecht S, Hanf V, Hartmann A, Beckmann MW, Press MF. Abstract P4-12-07: CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-12-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mechanisms of progress and recurrence of early breast cancer (BC) have gained importance since several targeted therapeutic options in metastatic breast cancer have been introduced over the last years, especially in hormone receptor positive BC. This study investigates the amplification of cell cycle regulator cyclin D1 gene (CCND1) amplification as one possible progression mechanism.
Patients & Methods: Patients from an unselected cohort of early BC patients were included into this study. A tissue microarray (TMA) was available for n=832 patients with early breast cancer. CCND1 amplification was assessed after FISH (Abbott Vysis LSI CCND1 SpectumOrange/CEP11 SpectrumGreen Probes Kit). A CCND1/CEP11-ratio ≥ 2.0 was considered as amplification. Staining was successful in 545 tumor cores. Amplification results were correlated with clinical patient and tumor characteristics and survival analyses were performed with regard to distant disease free survival and overall survival.
Results: CCND1 amplification was found in 13.6% of patients. Triple negative, luminal A like, luminal B like and HER2 positive tumors were amplified in 7.5%, 7.8%, 18.6% and 15.7% respectively (p = 0.010). CCDN1 amplification was significantly associated with a higher grading and a higher body mass index. Furthermore an amplification was seen more frequently in lobular BC and ductal BC than other histological subtypes.
Survival analysis showed a reduced DDFS for patients with CCDN1-amplification. 5 year DDFS rates were 90.6% for non-amplified tumors and 86.0% for amplified tumors (p, log-rank =0.066 ). 5 year OS rates were 93.0% for non-amplified tumors and 90.1% for amplified tumors (p, log-rank =0.119).
Adjusted for age, tumor size, nodal status and molecular subtype, cox regression showed HR of 1.3 (95% CI: 0.76-2.5, p=0.46) for DDFS and a HR of 1.33 (95% CI: 0.7-2.53, p=0.38) for OS.
Conclusion: With a 13.6% prevalence in all breast cancer patients, mainly present in luminal B like cancers, CCND1-amplification is a genetic aberration associated with an unfavorable prognosis. Within hormone receptor positive women CCDN1 amplification might play a role in treatment resistance mechanisms in early breast cancer patients.
Citation Format: Hanf DC, Fasching PA, Villalobos IE, Gasparyan A, Wachter D, Santiago A, Guzman R, Weihbrecht S, Hanf V, Hartmann A, Beckmann MW, Press MF. CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-12-07.
Collapse
Affiliation(s)
- DC Hanf
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - PA Fasching
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - IE Villalobos
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - A Gasparyan
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - D Wachter
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - A Santiago
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - R Guzman
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - S Weihbrecht
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - V Hanf
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - A Hartmann
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - MW Beckmann
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| | - MF Press
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Breast Center Klinikum Fuerth, Fuerth, Germany; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
| |
Collapse
|
16
|
Ortega AP, Gonzalez-Diaz S, Arias-Cruz A, Macias-Weinmann A, Monge-Ortega O, Ibarra-Chávez J, Macouzet-Sánchez C, Ramos Valencia L, De Lira Quezada C, Guzman R. P138 Evaluation of functional capacity by six-minute walk test in pediatric asthma patients. Ann Allergy Asthma Immunol 2016. [DOI: 10.1016/j.anai.2016.09.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Shafiq ul Hassan M, Zhang G, Latifi K, Oliver J, Hunt D, Guzman R, Balagurunathan Y, Mackin D, Court L, Gillies R, Moros E. MO-DE-207B-04: Impact of Reconstruction Field of View On Radiomics Features in Computed Tomography (CT) Using a Texture Phantom. Med Phys 2016. [DOI: 10.1118/1.4957253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
18
|
Press MF, Villalobos I, Santiago A, Guzman R, Cervantes M, Gasparyan A, Campeau A, Ma Y, Tsao-Wei DD, Groshen S. Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. Arch Pathol Lab Med 2016; 140:1250-1258. [PMID: 27081877 DOI: 10.5858/arpa.2016-0009-oa] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Context .- Evaluation of HER2 gene amplification by fluorescence in situ hybridization (FISH) was changed by recent American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines. Objective . -To determine frequencies and assess patterns of HER2 protein expression for each ASCO-CAP guideline FISH category among 7526 breast cancers accrued to our consultation practice. Design .- We retrospectively reevaluated the HER2 FISH status of breast cancers in our consultation practice according to ASCO-CAP FISH guidelines, and documented HER2 protein levels in each category. Results . -According to new guidelines, 17.7% of our consultation breast cancers were "ISH-positive" with HER2:CEP17 FISH ratios ≥2.0 and average HER2 gene copies per cell ≥4.0 (group 1); 0.4% were "ISH-positive" with ratios ≥2.0 and average copies <4.0 (group 2); 0.6% were "ISH-positive" with ratios <2.0 and average copies ≥6.0 (group 3); 4.6% were "ISH-equivocal" with ratios <2.0 and average copies ≥4.0 and <6.0 (group 4); and 76.7% were "ISH-negative" with ratios <2.0 and average copies <4.0 (group 5). However, only groups 1 (HER2 amplified) and 5 (HER2 not amplified) agreed with our previously reported status, and only these groups demonstrated the expected immunohistochemistry status, overexpression and low expression, respectively. Groups 2 and 4 breast cancers lacked overexpression, whereas group 3 was not significantly associated with either increased or decreased HER2 expression. Conclusions .- Although the status of approximately 95% of our cases (groups 1 and 5) is not affected by the new guidelines, those of the other 5% (groups 2-4) conflict with previous HER2 gene amplification status and with HER2 status by immunohistochemistry.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Susan Groshen
- From the Departments of Pathology (Drs Press and Ma; Mss Villalobos, Santiago, Guzman, Cervantes, and Campeau; and Mr Gasparyan) and Preventive Medicine (Ms Tsao-Wei and Dr Groshen), Norris Comprehensive Cancer Center, University of Southern California, Los Angeles
| |
Collapse
|
19
|
Reganne M, Röthlisberger M, Guzman R, Schaefer D, Kalbermatten D, Madduri S. Dual Functional Collagen Nerve Conduits for Bridging Critical Nerve Gaps. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Fisch U, Brégère C, Chicha L, Guzman R. Phenotypical Characterization of Microglia in the Subventricular Zone after Neonatal Hypoxia-ischemia in Rat. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Röthlisberger M, Zumofen D, Schatlo B, Stienen M, Zumofen D, Sailer M, Fung C, Burkhardt J, Tok S, D'Alonzo D, Marbacher S, Hiroki D, Dell-Kuster S, Achermann R, Corniola M, Bervini D, Fathi A, Daniel R, Hildebrandt G, Regli L, Reinert M, Raabe A, Fandino J, Bijlenga P, Schaller K, Keller E, Mariani L, Guzman R. Clinical and Radiological Characteristics of Aneurysmal Subarachnoid Hemorrhage in Older Adults. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Schatlo B, Fung C, Stienen M, Fathi A, Fandino J, Smoll N, Tok S, Daniel R, Zumofen D, Burkhard J, Dan-Ura H, Röthlisberger M, Reinert M, Winkler K, Ahlborn P, Mendes-Pereira V, D́Alonzo D, Seule M, Kerkeni H, Bervini D, Sailer M, Kuhlen D, Remonda L, Rohde V, Mostaguir K, Marbacher S, Valsecchi D, Corniola M, Schöni D, Woernle C, Regli L, Levivier M, Hildebrandt G, Mariani L, Beck J, Guzman R, Raabe A, Bijlenga P, Keller E, Schaller K. Incidence, Therapy, and Outcome of Aneurysmal Subarachnoid Hemorrhage. The Swiss Study on Aneurysmal Subarachnoid Hemorrhage (Swiss SOS). J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Röthlisberger M, Madduri S, Marbacher S, Schaefer D, Kalbermatten D, Mariani L, Guzman R. Modular Bioactive Scaffold for Facial Nerve Reconstruction. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Soleman J, Thieringer F, Beinemann J, Oesch V, Kunz C, Guzman R. Computer-Assisted Virtual Planning and Surgical Template Fabrication for Fronto-orbital Advancement. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Bregere C, Fisch U, Lieb S, Sailer M, Chicha L, Goepfert F, Kremer T, Guzman R. Doublecortin in the Cerebrospinal Fluid Is a Candidate Biomarker of Neurogenesis after Neonatal Hypoxia Ischemia Brain Injury in Rats. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Stienen M, Corniola MV, Smoll N, Burkhardt JK, Fung C, Schöni D, Röthlisberger M, Bervini D, Valsecchi D, Arrighi M, Maduri R, Danura H, Fathi AR, Keller E, Regli L, Fandino J, Hildebrandt G, Guzman R, Schatlo B, Schaller K, Bijlenga P. Decompressive Hemicraniectomy in Aneurysmal Subarachnoid Hemorrhage—Insights from a Swiss National Database (Swiss SOS). J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Dulemba J, Guzman R, Mirzakhani P. Evaluation of a Robotic Uterine Manipulation. J Minim Invasive Gynecol 2014. [DOI: 10.1016/j.jmig.2014.08.740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
28
|
Soleman J, Soleman J, Datta A, Strozzi S, Ramelli G, Mariani L, Mariani Luigi L, Guzman R, Guzman R. Implantation of Vagal Nerve Stimulation in Children. J Neurol Surg A Cent Eur Neurosurg 2014. [DOI: 10.1055/s-0034-1383772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Press MF, Grob T, Marx A, Villalobos I, Santiago A, Guzman R, Gagnon RC, Arenas-Elliott C, Ellis CE. Concordance study of HER2 fluorescence in situ hybridization (FISH) assays in upper gastrointestinal (UGI) adenocarcinomas. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.4072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Tobias Grob
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Andreas Marx
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
30
|
Press OA, Guzman R, Cervantes M, Santiago A, Press MF. Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods Mol Biol 2014; 1180:181-207. [PMID: 25015148 DOI: 10.1007/978-1-4939-1050-2_10] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The use of human epidermal growth factor receptor type 2 (HER2) gene amplification and overexpression as a molecular predictive marker has become critically important for proper selection of breast cancer patients for treatment with targeted therapeutic agents such as trastuzumab, lapatinib, pertuzumab, and T-DM1. A high level of sensitivity and specificity of molecular tests for this alteration is desirable. The American Society of Clinical Oncology and College of American Pathology have jointly established consensus guidelines to standardize characterization of this alteration in breast cancers. This chapter provides a brief overview of pre-analytic and analytical processing of breast specimens as well as subsequent molecular evaluation for HER2 status.
Collapse
Affiliation(s)
- Oliver A Press
- Department of Pathology, USC Keck School of Medicine, Los Angeles, CA, USA
| | | | | | | | | |
Collapse
|
31
|
Abstract
Neonatal hypoxic-ischemic insults are a significant cause of pediatric encephalopathy, developmental delays, and spastic cerebral palsy. Although the developing brain's plasticity allows for remarkable self-repair, severe disruption of normal myelination and cortical development upon neonatal brain injury are likely to generate life-persisting sensory-motor and cognitive deficits in the growing child. Currently, no treatments are available that can address the long-term consequences. Thus, regenerative medicine appears as a promising avenue to help restore normal developmental processes in affected infants. Stem cell therapy has proven effective in promoting functional recovery in animal models of neonatal hypoxic-ischemic injury and therefore represents a hopeful therapy for this unmet medical condition. Neural stem cells derived from pluripotent stem cells or fetal tissues as well as umbilical cord blood and mesenchymal stem cells have all shown initial success in improving functional outcomes. However, much still remains to be understood about how those stem cells can safely be administered to infants and what their repair mechanisms in the brain are. In this review, we discuss updated research into pathophysiological mechanisms of neonatal brain injury, the types of stem cell therapies currently being tested in this context, and the potential mechanisms through which exogenous stem cells might interact with and influence the developing brain.
Collapse
Affiliation(s)
- L Chicha
- Department of Biomedicine, University of Basel, Basel, Switzerland
| | | | | |
Collapse
|
32
|
Mohedano M, Guzman R, Arrabal R, López Lacomba JL, Matykina E. Bioactive plasma electrolytic oxidation coatings-The role of the composition, microstructure, and electrochemical stability. J Biomed Mater Res B Appl Biomater 2013; 101:1524-37. [DOI: 10.1002/jbm.b.32974] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2013] [Revised: 04/11/2013] [Accepted: 04/23/2013] [Indexed: 12/15/2022]
Affiliation(s)
- M. Mohedano
- Departamento de Ciencia de Materiales, Facultad de Ciencias Químicas; Universidad Complutense; 28040 Madrid Spain
| | - R. Guzman
- Grupo de Ingeniería de Tejidos, Instituto de Estudios Biofuncionales; Universidad Complutense; 28040 Madrid Spain
| | - R. Arrabal
- Departamento de Ciencia de Materiales, Facultad de Ciencias Químicas; Universidad Complutense; 28040 Madrid Spain
| | - J.-L. López Lacomba
- Grupo de Ingeniería de Tejidos, Instituto de Estudios Biofuncionales; Universidad Complutense; 28040 Madrid Spain
| | - E. Matykina
- Departamento de Ciencia de Materiales, Facultad de Ciencias Químicas; Universidad Complutense; 28040 Madrid Spain
| |
Collapse
|
33
|
Guzman R, Roa G, Rodriguez W, Cordoba J, Villalba A. AB0285 First real life experience with certolizumab pegol in rheumathoid arthritis (ra) in latinamerica. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Andres R, Andereggen L, Ducray A, Mordasini P, Guzman R, Barth A, Raabe A, Widmer H. Intracerebral Hemorrhage Affects the Extrapyramidal System and Promotes Endogenous Neurogenesis in the Subventricular Zone and Hippocampus. J Neurol Surg A Cent Eur Neurosurg 2012. [DOI: 10.1055/s-0032-1316234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
35
|
Adoue D, Navarra S, Petri M, Gallacher A, Guzman R, Furie R, Thomas M, Zamani O, Levy R, Van Vollenhoven R, Cerva R, Wallace D. Profil de tolérance du bélimumab, inhibiteur de BLyS, chez des patients atteints de lupus systémique (LS) actif dans les essais cliniques de phase 2 et 3. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29:859-67. [PMID: 21189395 PMCID: PMC3068060 DOI: 10.1200/jco.2009.27.5644] [Citation(s) in RCA: 162] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Accepted: 09/23/2010] [Indexed: 01/03/2023] Open
Abstract
PURPOSE Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers. METHODS A total of 4,943 breast cancers were analyzed for alterations in TOP2A and HER2. Primary tumor tissues from patients with metastatic breast cancer treated in a trial of chemotherapy plus/minus trastuzumab were studied for amplification/deletion of TOP2A and HER2 as a test set followed by evaluation of malignancies from two separate, large trials for changes in these same genes as a validation set. Association between these alterations and clinical outcomes was determined. RESULTS Test set cases containing HER2 amplification treated with doxorubicin and cyclophosphamide (AC) plus trastuzumab, demonstrated longer progression-free survival compared to those treated with AC alone (P = .0002). However, patients treated with AC alone whose tumors contain HER2/TOP2A coamplification experienced a similar improvement in survival (P = .004). Conversely, for patients treated with paclitaxel, HER2/TOP2A coamplification was not associated with improved outcomes. These observations were confirmed in a larger validation set, where HER2/TOP2A coamplification was again associated with longer survival when only anthracycline-containing chemotherapy was used for treatment compared with outcome in HER2-positive cancers lacking TOP2A coamplification. CONCLUSION In a study involving nearly 5,000 breast malignancies, both test set and validation set demonstrate that TOP2A coamplification, not HER2 amplification, is the clinically useful predictive marker of an incremental response to anthracycline-based chemotherapy. Absence of HER2/TOP2A coamplification may indicate a more restricted efficacy advantage for breast cancers than previously thought.
Collapse
Affiliation(s)
- Michael F Press
- Norris Comprehensive Cancer Center, University of Southern California, CA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Woo K, Qu X, Babaev V, Linton M, Guzman R, Fazio S, Baldwin H. L1 Tie1 ATTENUATION RESULTS IN A LOCATION-SPECIFIC AND SHEAR STRESS-DEFINED REDUCTION IN ATHEROSCLEROSIS. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70061-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
38
|
Backhouse MR, Keenan AM, Young A, James D, Cox N, Williams P, Musa R, Helliwell PS, Kingsley GH, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Ibrahim F, Taylor H, Kowalczyk A, Maddison PJ, Scott DL, D'Cruz D, Tanasescu C, Navarra S, Guzman R, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez RE, Leon MG, Hall S, Lan JL, Kim HY, Pineda L, Zhong J, Freimuth WW. BSR and BHPR Plenary Oral [OP1-OP3]: OP1. Use of Conservative and Surgical Foot Care in Rheumatoid Arthritis: The Eras Cohort. Rheumatology (Oxford) 2010; 49 Suppl 1:i1-167. [DOI: 10.1093/rheumatology/keq700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Wang GX, Luo LL, Yin TY, Li Y, Jiang T, Ruan CG, Guidoin R, Chen YP, Guzman R. Ultrasonic atomization and subsequent desolvation for monoclonal antibody (mAb) to the glycoprotein (GP) IIIa receptor into drug eluting stent. J Microencapsul 2010. [DOI: 10.3109/02652040903046798] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
40
|
Rizvi S, Komalavilas P, Guzman R, Dattilo J, Brophy C. Expression of the Heat Shock Protein, HSPB1, Is Associated with Impaired Smooth Muscle Relaxation. J Surg Res 2010. [DOI: 10.1016/j.jss.2009.11.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Wang GX, Luo LL, Yin TY, Li Y, Jiang T, Ruan CG, Guidoin R, Chen YP, Guzman R. Ultrasonic atomization and subsequent desolvation for monoclonal antibody (mAb) to the glycoprotein (GP) IIIa receptor into drug eluting stent. J Microencapsul 2009; 27:105-14. [PMID: 19566394 DOI: 10.1080/02652040903046798] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
An eluting-stent system with mAb dispersed in the PLLA (poly (L-lactic acid)) was validated in vitro. Specifically designed spray equipment based on the principle of ultrasonic atomization was used to produce a thin continuous PLLA (poly (L-lactic acid)) polymer coating incorporating monoclonal antibody (mAb). This PLLA coating was observed in light microscopy (LM) and scanning electron microscopy (SEM). The concentration of the monoclonal antibody (mAb) to the platelet glycoprotein (GP) IIIa receptor and the eluting rate were then measured by a radioisotope technique with (125)I-labelled GP IIIa mAb. An in vitro perfusion circuit was designed to evaluate the release rates at different velocities (10 or 20 ml min(-1)). The PLLA coating was thin and transparent, uniformly distributed on the surface of the stent. Three factors influenced its thickness: PLLA concentration, duration and gas pressure. The concentration of mAb was influenced by the duration of absorption and the concentration of the mAb solution; the maximum was 1662.23 + or - 38.83 ng. The eluting rate was fast for the first 2 h, then decreased slowly and attained 80% after 2 weeks. This ultrasonic atomization spray equipment and technological process to prepare protein eluting-stents were proved to be effective and reliable.
Collapse
Affiliation(s)
- G X Wang
- Bioengineering College of Chongqing University, Chongqing, PR China.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clin Cancer Res 2008; 14:7861-70. [DOI: 10.1158/1078-0432.ccr-08-1056] [Citation(s) in RCA: 145] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Guzman R, Lovblad KO, Altrichter S, Remonda L, de Koning P, Andres RH, El-Koussy M, Kelly ME, Reiber JHC, Schroth G, Oswald H, Barth A. Clinical validation of an automated vessel-segmentation software of the extracranial-carotid arteries based on 3D-MRA: a prospective study. J Neuroradiol 2008; 35:278-85. [PMID: 18707758 DOI: 10.1016/j.neurad.2008.07.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To determine the accuracy of automated vessel-segmentation software for vessel-diameter measurements based on three-dimensional contrast-enhanced magnetic resonance angiography (3D-MRA). METHOD In 10 patients with high-grade carotid stenosis, automated measurements of both carotid arteries were obtained with 3D-MRA by two independent investigators and compared with manual measurements obtained by digital subtraction angiography (DSA) and 2D maximum-intensity projection (2D-MIP) based on MRA and duplex ultrasonography (US). In 42 patients undergoing carotid endarterectomy (CEA), intraoperative measurements (IOP) were compared with postoperative 3D-MRA and US. RESULTS Mean interoperator variability was 8% for measurements by DSA and 11% by 2D-MIP, but there was no interoperator variability with the automated 3D-MRA analysis. Good correlations were found between DSA (standard of reference), manual 2D-MIP (rP=0.6) and automated 3D-MRA (rP=0.8). Excellent correlations were found between IOP, 3D-MRA (rP=0.93) and US (rP=0.83). CONCLUSION Automated 3D-MRA-based vessel segmentation and quantification result in accurate measurements of extracerebral-vessel dimensions.
Collapse
Affiliation(s)
- R Guzman
- Department of Neurosurgery, Inselspital, Bern, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Guzman R, Altrichter S, El-Koussy M, Gralla J, Weis J, Barth A, Seiler RW, Schroth G, Lövblad KO. Contribution of the apparent diffusion coefficient in perilesional edema for the assessment of brain tumors. J Neuroradiol 2008; 35:224-9. [PMID: 18420272 DOI: 10.1016/j.neurad.2008.02.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES Diffusion-weighted MRI is sensitive to molecular motion and has been applied to the diagnosis of stroke. Our intention was to investigate its usefulness in patients with brain tumor and, in particular, in the perilesional edema. METHODS We performed MRI of the brain, including diffusion-weighted imaging and mapping of the apparent diffusion coefficient (ADC), in 16 patients with brain tumors (glioblastomas, low-grade gliomas and metastases). ADC values were determined by the use of regions of interest positioned in areas of high signal intensities as seen on T2-weighted images and ADC maps. Measurements were taken in the tumor itself, in the area of perilesional edema and in the healthy contralateral brain. RESULTS ADC mapping showed higher values of peritumoral edema in patients with glioblastoma (1.75 x 10(-3)mm(2)/s) and metastatic lesions (1.61 x 10(-3)mm(2)/s) compared with those who had low-grade glioma (1.40 x10(-3)mm(2)/s). The higher ADC values in the peritumoral zone were associated with lower ADC values in the tumor itself. CONCLUSIONS The higher ADC values in the more malignant tumors probably reflect vasogenic edema, thereby allowing their differentiation from other lesions.
Collapse
Affiliation(s)
- R Guzman
- Department of Neurosurgery, Inselspital, University of Berne, Berne, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Andres RH, Guzman R, Weis J, Schroth G, Barth A. Granuloma formation and occlusion of an unruptured aneurysm after wrapping. Acta Neurochir (Wien) 2007; 149:953-8; discussion 958. [PMID: 17676408 DOI: 10.1007/s00701-007-1260-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2007] [Accepted: 05/22/2007] [Indexed: 11/29/2022]
Abstract
Excessive granulomatous foreign-body reaction is a very rare complication after wrapping of intracranial aneurysms. The pathogenetic mechanisms underlying this process are unknown. We report on a patient who developed a space-occupying granulomatous abscess after wrapping of an unruptured aneurysm of the M2/M3 bifurcation. The patient underwent revision craniotomy for abscess removal. The aneurysm was explored and found to be completely thrombosed and excluded from the circulation. Exuberant granulomatous foreign-body reaction was pathologically confirmed and Candida parapsilosis was isolated from the pus. The patient underwent an antifungal treatment regimen and recovered with no residual neurological deficits. Our findings support the assumption that a low-grade infectious process might trigger excessive inflammatory reaction after wrapping. We suggest that this process may also result in complete thrombosis of cerebral aneurysms, which is otherwise a rarely observed phenomenon.
Collapse
Affiliation(s)
- R H Andres
- Department of Neurosurgery, University of Berne, Inselspital, Berne, Switzerland.
| | | | | | | | | |
Collapse
|
46
|
Guzman R, Buchbinder S, Mansergh G, Vittinghoff E, Marks G, Wheeler S, Colfax GN. Communication of HIV viral load to guide sexual risk decisions with serodiscordant partners among San Francisco men who have sex with men. AIDS Care 2007; 18:983-9. [PMID: 17012089 DOI: 10.1080/09540120500497908] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The objective of this study was to estimate frequency and correlates of discussing HIV viral load (VL) with serodiscordant sex partners to guide decisions about sexual activities among men who have sex with men (MSM). We conducted a cross-sectional survey of 573 San Francisco MSM. Among 507 who knew their HIV status, 397 (78%) were familiar with the term 'viral load', and half (n=199) had a serodiscordant partner in the prior year. These 199 respondents (n=130 [65%] HIV-positive; n=69 [35%] HIV-negative) were the focus of this analysis. A majority (n=111, 56%) discussed VL in the prior year with serodiscordant partners specifically to guide decisions about sexual risk behaviour. Discussion was more common among HIV-positive than HIV-negative participants (adjusted odds ratio [AOR], 3.5; 95% confidence interval [CI], 1.6-7.6), and African Americans compared to whites (AOR, 3.7; 95% CI, 1.5-9.5). HIV-negative men who discussed VL were more concerned about becoming infected, but also more willing to engage in risky behaviour with a partner whose VL is undetectable, than men not discussing VL. Some HIV-negative men may be discussing VL to engage in higher risk behaviour upon learning of an HIV-positive partner's undetectable VL. Interventions targeting MSM should explain that while risk of transmission is likely reduced with a low blood plasma VL, it is not necessarily eliminated.
Collapse
Affiliation(s)
- R Guzman
- AIDS Office, San Francisco Department of Public Health, San Francisco, CA 94102, USA.
| | | | | | | | | | | | | |
Collapse
|
47
|
Guidoin R, Zhang Z, Douville Y, Baslé MF, Grizon F, Marinov GR, Zarins CK, Legrand AP, Guzman R. Polymethylmethacrylate (PMMA) as an embedding medium preserving tissues and foreign materials encroaching in endovascular devices. Artif Cells Blood Substit Immobil Biotechnol 2006; 34:349-66. [PMID: 16809135 DOI: 10.1080/10731190600684041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Problems of displacement, poor healing, degradation of the polymers and corrosion of the metallic frame in endovascular devices still require in-depth investigations. As the tissues and the foreign materials are in close contact, it is of paramount importance to efficiently investigate the interfaces between them. Inclusion in polymethymethacrylate (PMMA) permits us to obtain thin slides and preserve the capacity to perform the appropriate stainings. An AneuRx prosthesis was harvested in bloc with the surrounding tissues at the autopsy of a patient 25 months post deployment in a 5.7 cm diameter AAA and sectioned in the direction of the blood flow in two halves. A cross-section of the encapsulated distal segment together with the surrounding aneuryshmal sac was embedded in polymethylmethacrylate (PMMA). Further to complete polymerization, slices of the specimen were cut on a precision banding saw under coolant. They were affixed onto methacrylate slides with a UV cured adhesive. Binding and polishing were done on a numeric grinder and slices 25 to 30 microm in thickness were stained with toluidine blue prior to observation in light microscopy. Additional slices were prepared for scanning electron microscopy and X-ray energy dispersive spectrometry for determination of the elemental composition of the Nitinol stent. The aortic wall did not demonstrate complete integrity along with its circumference. Some areas of rupture were noted. The content of the sac was heavily shrunk and was mostly acellular. The walls of the device were very well encapsulated. The PMMA embedding permitted the polyester wall, the Nitinol wire and the collagen to keep in close contact. Scanning electron microscopy involved backscattered electrons and confirmed the corrosion the Nitinol wire at the boundary with living tissues. Based upon the results obtained, we believe that PMMA embedding is the most appropriate method to process endovascular devices for histological and material investigation. Needless to say, that paraffin embedding would have not been feasible for such a big size specimen involving different materials.
Collapse
Affiliation(s)
- R Guidoin
- Department of Surgery, Laval University and Quebec Biomaterials Institute, St François d'Assise Hospital, Quebec, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Mansergh G, Shouse RL, Marks G, Guzman R, Rader M, Buchbinder S, Colfax GN. Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men. Sex Transm Infect 2006; 82:131-4. [PMID: 16581738 PMCID: PMC2564684 DOI: 10.1136/sti.2005.017129] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES There is evidence that methamphetamine and sildenafil (Viagra) use are associated with sexual risk behaviour among men who have sex with men (MSM). We investigated the association of methamphetamine, sildenafil, and other substance use with unprotected receptive and insertive anal sex among MSM by conducting an encounter specific analysis. METHODS Data were from a cross sectional, community based survey of MSM in San Francisco regarding behaviour during their most recent anal sex encounter. Mulitvariate regression analysed independent associations of specific substance use and demographic variables with unprotected anal sex behaviours. RESULTS The sample (n = 388) was diverse in race/ethnicity, age, income, education, HIV status, and homosexual/bisexual identification. More than half (53%) reported unprotected anal sex, including insertive (29%) and receptive (37%) during their most recent anal sex encounter; 12% reported unprotected insertive and 17% reported unprotected receptive anal sex with an HIV discordant or unknown partner. Methamphetamine was used by 15% and sildenafil was used by 6% of the men before or during the encounter; 2% used both drugs. In multivariate analysis controlling for demographic factors and other substance use, methamphetamine use was associated with unprotected receptive (odds ratio (OR), 2.03; 95% confidence interval (CI), 1.09 to 3.76) and sildenafil use was associated with unprotected insertive (OR, 6.51; CI, 2.46 to 17.24) anal sex. Effects were stronger with HIV discordant or unknown sex partners specifically. CONCLUSION Encounter specific associations of methamphetamine and sildenafil use with unprotected receptive and insertive anal sex, respectively, indicate the importance of assessment specificity and tailoring risk reduction efforts to address certain drugs and sexual behavioural roles among MSM.
Collapse
Affiliation(s)
- G Mansergh
- CDC Division of HIV/AIDS Prevention, 1600 Clifton Road, Mailstop E-37, Atlanta, GA 30333, USA.
| | | | | | | | | | | | | |
Collapse
|
49
|
Guidoin R, Zhang Z, Douville Y, Bonny JM, Renou JP, Baslé MF, Zarins CK, Legrand AP, Guzman R. MRI virtual biopsies: analysis of an explanted endovascular device and perspectives for the future. ACTA ACUST UNITED AC 2006; 34:241-61. [PMID: 16537177 DOI: 10.1080/10731190600581825] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Information that can be obtained by magnetic resonance imaging (MRI) of explanted endovascular devices must be validated as this method is non-destructive. Histology of such a device together with its encroached tissues can be elegantly performed after polymethymethacrylate (PMMA) embedding, but this approach requires destruction of the specimen. The issue is therefore to determine if the MRI is sufficient to fully validate an explanted device based upon the characterization of an explanted specimen. An AneuRx device deployed percutaneously 25 months earlier in a 75-year-old patient was removed en bloc at autopsy together with the surrounding aneurysmal sac and segments of the upstream and downstream arteries. Macroscopic pictures were taken and a slice of the cross-section was processed for histology after polymethylmethacrylate (PMMA) embedding. For the magnetic resonance imaging investigation, the device was inserted in a Biospec 4.7 T MRI system with a 20 mm diameter birdcage resonator used for both emission and reception. A Spin-Echo (SE) was used to acquire both T1 proton density (PD) and T2 weighted images. A gradient-echo (GE) sampling of a free induction decay (GESFID) was used to generate multiple GE images using a single excitation pulse so that four images at different TE were obtained in the same acquisition. The selected explanted device was outstandingly well-healed compared to most devices harvested from humans. No inflammatory process was observed in contact or at distance of the materials. In MRI T1 images display no specific contrast and were homogeneous in the different tissues. The contrast was improved on proton density weighed images. On the T2 weighed images, the different areas were well identified. The diffusion images displayed in the surrounding B region had the greatest diffusion coefficient and the greatest anisotropy. The MRI analysis of the explanted AneuRx device illustrates the possibilities of this technique to characterize the interaction of the endovascular graft with the surrounding tissues. MRI is a breakthrough to investigate explanted medical devices but it also can be advantageously used in vivo to obtain virtual biopsies, because real biopsies to determine the 3 Bs (biocompatibility, biofunctionality and bioresilience) cannot be carried out as they could obviously initiate infection and degradation of the foreign materials.
Collapse
Affiliation(s)
- R Guidoin
- Department of Surgery, Laval University and Quebec Biomaterials Institute, St. François d'Assise Hospital, Quebec, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Yang Y, Guzman R, Deymier PA, Umnov M, Hoying J, Raghavan S, Palusinski O, Zelinski BJJ. Adsorption of a microtubule on a charged surface affects its disassembly dynamics. J Nanosci Nanotechnol 2005; 5:2050-6. [PMID: 16430139 DOI: 10.1166/jnn.2005.510] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
The dynamics of disassembly of microtubules deposited on surfaces is shown to be strongly dependent on the electrostatic interaction between the microtubule and the substrate. Fluorescence microscopy of microtubules adsorbed on a Poly-L-Lysine film and immersed in pure water show a drastic decrease in disassembly velocity compared to the microtubules in bulk water solutions. While microtubules suspended in pure water disassemble in seconds, the dissociation velocity of microtubules adsorbed on a Poly-L-Lysine film ranges from 0.8 to 1.0 microm/min in pure water. Kinetic Monte Carlo simulations of the microtubule dynamics indicate that a decrease in the dissociation velocity of unstable microtubules can be achieved by reducing the heterodimer dissociation rate constant of tubulin heterodimers constituting a single protofilament, adsorbed to the Poly-L-Lysine film. This model suggests that the reduction of the dissociation velocity originates from the electrostatic interactions between the positively charged amino groups of the Poly-L-Lysine film and the negatively charged microtubule surface.
Collapse
Affiliation(s)
- Yi Yang
- Department of Materials Science and Engineering, Nano-Biomolecular Engineering Science and Technology (n-BEST) Program, The University of Arizona, Tucson AZ 85721, USA
| | | | | | | | | | | | | | | |
Collapse
|